ReviewOncotarget2018
Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review.
Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Unexpected Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma Harboring KRAS G12R with an Ultra-Low-VAF SMAD4 Mutation: A Case Report and Mini-Review.Reports (MDPI) · 2026Article
- Review
- Bibliometric review of journal articles on pancreatic cancer: insights into productivity and impact.Annals of pancreatic cancer · 2025Article
- Global hotspots and future directions for drugs to improve the skin flap survival: A bibliometric and visualized review.Journal of pharmaceutical analysis · 2024Review
- Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma.Cancers · 2023Article
- Emerging trends and research foci in autophagy of pancreatic cancer: a bibliometric and visualized study.Frontiers in oncology · 2023Article
- Sesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer.Molecules (Basel, Switzerland) · 2022Review
- Article
- Bibliometric Analysis of Global Research on Cancer Photodynamic Therapy: Focus on Nano-Related Research.Frontiers in pharmacology · 2022Article
- Emerging current trends and research focus related to pancreatic cancer metabolism: A bibliometric and visualized analysis.Frontiers in oncology · 2022Article
- Emerging Trends and Research Foci in Tumor Microenvironment of Pancreatic Cancer: A Bibliometric and Visualized Study.Frontiers in oncology · 2022Article
- Precision Therapy of Pancreatic Cancer: From Bench to Bedside.Visceral medicine · 2020Review
- Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer.Molecular therapy oncolytics · 2020Article
- Small molecule inhibitors in pancreatic cancer.RSC medicinal chemistry · 2020Review
- Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.Cancer communications (London, England) · 2020Article
- Can Elderly Patients With Pancreatic Cancer Gain Survival Advantages Through More Radical Surgeries? A SEER-Based Analysis.Frontiers in oncology · 2020Article
- Targeted Delivery of C/EBPα-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC.Molecular therapy. Nucleic acids · 2019Article
- Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy.The FEBS journal · 2019Review
- Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.Cancer research · 2019Article
- Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.Clinical and translational medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy. We also point out the need for molecular selection for low prevalence subtypes. Key insights sourced from these pivotal trials should improve clinical outcomes for this devastating cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.